| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms, Castration-Resistant | 14 | 2024 | 475 | 2.430 |
Why?
|
| Tissue Extracts | 6 | 2023 | 50 | 1.680 |
Why?
|
| Ipilimumab | 14 | 2024 | 758 | 1.610 |
Why?
|
| CTLA-4 Antigen | 13 | 2021 | 667 | 1.440 |
Why?
|
| Prostatic Neoplasms | 18 | 2024 | 5990 | 1.410 |
Why?
|
| Myocarditis | 3 | 2024 | 195 | 1.180 |
Why?
|
| Cancer Vaccines | 5 | 2021 | 750 | 1.080 |
Why?
|
| Immunotherapy | 17 | 2024 | 3532 | 0.950 |
Why?
|
| Antineoplastic Agents, Immunological | 5 | 2020 | 1335 | 0.890 |
Why?
|
| Myositis | 1 | 2024 | 85 | 0.880 |
Why?
|
| Abiraterone Acetate | 6 | 2024 | 90 | 0.750 |
Why?
|
| Antibodies, Monoclonal | 11 | 2023 | 4510 | 0.730 |
Why?
|
| Immunotherapy, Active | 1 | 2019 | 49 | 0.660 |
Why?
|
| Tumor Microenvironment | 12 | 2023 | 2984 | 0.630 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2024 | 1654 | 0.630 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2024 | 631 | 0.560 |
Why?
|
| Neutrophils | 1 | 2021 | 870 | 0.560 |
Why?
|
| Lymphocyte Count | 1 | 2016 | 485 | 0.500 |
Why?
|
| B7-1 Antigen | 4 | 2005 | 86 | 0.500 |
Why?
|
| Clonal Evolution | 1 | 2016 | 251 | 0.480 |
Why?
|
| Immunomodulation | 1 | 2016 | 253 | 0.470 |
Why?
|
| Androgen Antagonists | 5 | 2024 | 434 | 0.460 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2024 | 16593 | 0.430 |
Why?
|
| T-Lymphocyte Subsets | 5 | 2019 | 595 | 0.400 |
Why?
|
| Biomarkers, Tumor | 9 | 2024 | 10698 | 0.400 |
Why?
|
| Colitis | 3 | 2019 | 344 | 0.390 |
Why?
|
| Antineoplastic Agents | 5 | 2023 | 14679 | 0.380 |
Why?
|
| B7-H1 Antigen | 6 | 2023 | 1057 | 0.360 |
Why?
|
| Urogenital Neoplasms | 2 | 2021 | 115 | 0.360 |
Why?
|
| Male | 44 | 2024 | 128454 | 0.350 |
Why?
|
| Molecular Targeted Therapy | 2 | 2019 | 2399 | 0.330 |
Why?
|
| Programmed Cell Death 1 Receptor | 5 | 2019 | 1088 | 0.320 |
Why?
|
| Phenylthiohydantoin | 2 | 2022 | 106 | 0.300 |
Why?
|
| B7 Antigens | 2 | 2019 | 84 | 0.300 |
Why?
|
| Antigens, CD | 5 | 2010 | 1436 | 0.290 |
Why?
|
| Neoplasms | 10 | 2024 | 15849 | 0.290 |
Why?
|
| Lymphocyte Activation | 7 | 2021 | 1733 | 0.290 |
Why?
|
| Humans | 58 | 2024 | 270947 | 0.280 |
Why?
|
| Receptors, Tumor Necrosis Factor | 5 | 2005 | 216 | 0.270 |
Why?
|
| Receptors, IgG | 2 | 2024 | 116 | 0.270 |
Why?
|
| Prednisone | 3 | 2024 | 1039 | 0.270 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2019 | 715 | 0.260 |
Why?
|
| Clinical Trials as Topic | 5 | 2023 | 3862 | 0.260 |
Why?
|
| T-Lymphocytes | 8 | 2017 | 3928 | 0.250 |
Why?
|
| Th1 Cells | 3 | 2021 | 260 | 0.220 |
Why?
|
| Adenocarcinoma | 2 | 2019 | 7936 | 0.220 |
Why?
|
| Middle Aged | 23 | 2024 | 90021 | 0.220 |
Why?
|
| Blood Proteins | 1 | 2004 | 299 | 0.210 |
Why?
|
| Aged | 20 | 2024 | 73161 | 0.200 |
Why?
|
| Hypophysitis | 1 | 2021 | 11 | 0.190 |
Why?
|
| Toxicity Tests | 1 | 2021 | 52 | 0.190 |
Why?
|
| Body Composition | 1 | 2024 | 609 | 0.190 |
Why?
|
| Listeria monocytogenes | 1 | 2021 | 61 | 0.190 |
Why?
|
| Kallikreins | 1 | 2021 | 87 | 0.190 |
Why?
|
| Adrenal Insufficiency | 1 | 2021 | 49 | 0.180 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 1010 | 0.180 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 537 | 0.180 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 719 | 0.180 |
Why?
|
| Taxoids | 2 | 2024 | 1008 | 0.170 |
Why?
|
| Mobile Applications | 1 | 2021 | 109 | 0.170 |
Why?
|
| Aged, 80 and over | 12 | 2024 | 30941 | 0.170 |
Why?
|
| Forkhead Transcription Factors | 3 | 2019 | 774 | 0.170 |
Why?
|
| Radium | 1 | 2021 | 97 | 0.170 |
Why?
|
| Autoimmune Hypophysitis | 1 | 2019 | 13 | 0.170 |
Why?
|
| Glucocorticoid-Induced TNFR-Related Protein | 1 | 2019 | 19 | 0.170 |
Why?
|
| Cell Lineage | 2 | 2019 | 706 | 0.170 |
Why?
|
| Graft Rejection | 1 | 2004 | 865 | 0.170 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2019 | 104 | 0.170 |
Why?
|
| Melanoma, Experimental | 2 | 2019 | 385 | 0.160 |
Why?
|
| Bone Neoplasms | 3 | 2021 | 2669 | 0.160 |
Why?
|
| Hypothyroidism | 1 | 2021 | 211 | 0.160 |
Why?
|
| Autoantibodies | 3 | 2019 | 598 | 0.160 |
Why?
|
| Receptors, Nerve Growth Factor | 3 | 2003 | 39 | 0.160 |
Why?
|
| Prostatectomy | 2 | 2021 | 1005 | 0.160 |
Why?
|
| Extracellular Vesicles | 1 | 2021 | 135 | 0.160 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 2018 | 36 | 0.160 |
Why?
|
| Thyrotoxicosis | 1 | 2018 | 22 | 0.160 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2019 | 219 | 0.160 |
Why?
|
| Cytokines | 6 | 2019 | 2836 | 0.150 |
Why?
|
| Peptides | 1 | 2004 | 1529 | 0.150 |
Why?
|
| Melanoma | 3 | 2018 | 5523 | 0.150 |
Why?
|
| Treatment Outcome | 8 | 2023 | 33827 | 0.150 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2018 | 161 | 0.150 |
Why?
|
| Prostate-Specific Antigen | 1 | 2021 | 1037 | 0.150 |
Why?
|
| Multicenter Studies as Topic | 1 | 2019 | 565 | 0.150 |
Why?
|
| Anilides | 1 | 2020 | 295 | 0.150 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2019 | 272 | 0.150 |
Why?
|
| Immunosuppressive Agents | 2 | 2023 | 1445 | 0.140 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 1312 | 0.140 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2018 | 263 | 0.140 |
Why?
|
| Pneumonia | 2 | 2020 | 796 | 0.140 |
Why?
|
| Gene Expression | 3 | 2021 | 3681 | 0.130 |
Why?
|
| Interleukin-7 | 1 | 2016 | 93 | 0.130 |
Why?
|
| Receptors, Androgen | 2 | 2020 | 922 | 0.130 |
Why?
|
| Proton Pump Inhibitors | 1 | 2019 | 271 | 0.130 |
Why?
|
| Radiography, Interventional | 1 | 2018 | 311 | 0.130 |
Why?
|
| Academies and Institutes | 1 | 2016 | 96 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 5 | 2022 | 1053 | 0.130 |
Why?
|
| Cohort Studies | 4 | 2021 | 9433 | 0.130 |
Why?
|
| Research Report | 1 | 2016 | 143 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 852 | 0.130 |
Why?
|
| Oncolytic Virotherapy | 2 | 2017 | 235 | 0.130 |
Why?
|
| Disease Susceptibility | 2 | 2016 | 534 | 0.130 |
Why?
|
| Positron-Emission Tomography | 1 | 2024 | 2198 | 0.130 |
Why?
|
| Urologic Neoplasms | 1 | 2017 | 209 | 0.130 |
Why?
|
| Radiopharmaceuticals | 1 | 2021 | 1338 | 0.130 |
Why?
|
| Animals | 23 | 2024 | 62771 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 10349 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2021 | 2851 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2016 | 296 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2024 | 3920 | 0.120 |
Why?
|
| Mice | 18 | 2024 | 35992 | 0.110 |
Why?
|
| Gene Products, gag | 1 | 2013 | 35 | 0.110 |
Why?
|
| Immunity | 1 | 2016 | 356 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2016 | 686 | 0.110 |
Why?
|
| Endogenous Retroviruses | 1 | 2013 | 43 | 0.110 |
Why?
|
| Interferon-gamma | 2 | 2016 | 1184 | 0.110 |
Why?
|
| RNA | 2 | 2021 | 1067 | 0.110 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2013 | 112 | 0.110 |
Why?
|
| Pyridines | 1 | 2020 | 1311 | 0.100 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2013 | 211 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 10 | 2018 | 7216 | 0.100 |
Why?
|
| Biomarkers | 3 | 2022 | 5106 | 0.100 |
Why?
|
| Patient Selection | 1 | 2019 | 2042 | 0.100 |
Why?
|
| Nitriles | 3 | 2023 | 943 | 0.090 |
Why?
|
| Immunization, Passive | 1 | 2011 | 193 | 0.090 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2020 | 1838 | 0.090 |
Why?
|
| Adoptive Transfer | 3 | 2017 | 435 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 3397 | 0.090 |
Why?
|
| Macrophages | 1 | 2017 | 1368 | 0.090 |
Why?
|
| Autoimmune Diseases | 2 | 2004 | 425 | 0.090 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2018 | 963 | 0.080 |
Why?
|
| Mice, Transgenic | 5 | 2018 | 4371 | 0.080 |
Why?
|
| Carboplatin | 2 | 2024 | 879 | 0.080 |
Why?
|
| Cell Line, Tumor | 6 | 2021 | 14864 | 0.080 |
Why?
|
| Female | 14 | 2024 | 148509 | 0.070 |
Why?
|
| Signal Transduction | 4 | 2016 | 12206 | 0.070 |
Why?
|
| Retrospective Studies | 8 | 2024 | 39694 | 0.070 |
Why?
|
| Heart Failure | 1 | 2021 | 2496 | 0.070 |
Why?
|
| Heterografts | 2 | 2024 | 745 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 3349 | 0.070 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2018 | 2435 | 0.070 |
Why?
|
| Adult | 6 | 2024 | 81555 | 0.070 |
Why?
|
| Diarrhea | 2 | 2020 | 731 | 0.070 |
Why?
|
| Immunologic Memory | 2 | 2019 | 380 | 0.070 |
Why?
|
| Prognosis | 4 | 2020 | 22458 | 0.070 |
Why?
|
| CD3 Complex | 2 | 2004 | 322 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 4399 | 0.070 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 2 | 2005 | 98 | 0.060 |
Why?
|
| Neoplasm Metastasis | 3 | 2020 | 5324 | 0.060 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2024 | 25 | 0.060 |
Why?
|
| Immune System | 2 | 2018 | 276 | 0.060 |
Why?
|
| Liver Regeneration | 1 | 2005 | 134 | 0.060 |
Why?
|
| Membrane Proteins | 4 | 2024 | 2953 | 0.060 |
Why?
|
| Receptors, Virus | 1 | 2005 | 154 | 0.060 |
Why?
|
| Succinimides | 1 | 2004 | 11 | 0.060 |
Why?
|
| Thiohydantoins | 1 | 2024 | 27 | 0.060 |
Why?
|
| Fluoresceins | 1 | 2004 | 74 | 0.060 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2004 | 43 | 0.060 |
Why?
|
| Time Factors | 3 | 2021 | 13112 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2004 | 2618 | 0.060 |
Why?
|
| Fatigue | 2 | 2021 | 1277 | 0.060 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2003 | 196 | 0.060 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2010 | 1331 | 0.050 |
Why?
|
| CD40 Antigens | 1 | 2003 | 107 | 0.050 |
Why?
|
| Benzamides | 2 | 2022 | 1883 | 0.050 |
Why?
|
| Islets of Langerhans | 1 | 2004 | 245 | 0.050 |
Why?
|
| CD28 Antigens | 1 | 2003 | 204 | 0.050 |
Why?
|
| Cell Division | 2 | 2004 | 2716 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 4 | 2016 | 2474 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2004 | 958 | 0.050 |
Why?
|
| Membrane Glycoproteins | 2 | 2004 | 1107 | 0.050 |
Why?
|
| Autoimmunity | 1 | 2004 | 268 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2004 | 467 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2019 | 3083 | 0.050 |
Why?
|
| Immune Tolerance | 1 | 2004 | 425 | 0.050 |
Why?
|
| Texas | 2 | 2024 | 6415 | 0.050 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2001 | 170 | 0.050 |
Why?
|
| Lymphoma, T-Cell | 1 | 2004 | 369 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 783 | 0.050 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2001 | 56 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2019 | 9307 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2019 | 7461 | 0.050 |
Why?
|
| Cells, Cultured | 4 | 2021 | 5782 | 0.050 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2021 | 171 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2004 | 3655 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2021 | 15253 | 0.050 |
Why?
|
| Hydrolases | 1 | 2021 | 132 | 0.050 |
Why?
|
| Gene Expression Profiling | 2 | 2024 | 5161 | 0.050 |
Why?
|
| Neoplasm Transplantation | 2 | 2014 | 1567 | 0.050 |
Why?
|
| Androstenes | 1 | 2020 | 44 | 0.050 |
Why?
|
| Th2 Cells | 1 | 2001 | 253 | 0.040 |
Why?
|
| Headache | 1 | 2021 | 174 | 0.040 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2019 | 36 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2003 | 696 | 0.040 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2002 | 266 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 5411 | 0.040 |
Why?
|
| Hypokalemia | 1 | 2019 | 61 | 0.040 |
Why?
|
| Dehydration | 1 | 2019 | 90 | 0.040 |
Why?
|
| Survival Rate | 3 | 2021 | 12516 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2004 | 1287 | 0.040 |
Why?
|
| Antigens | 1 | 2019 | 288 | 0.040 |
Why?
|
| Osteoclasts | 1 | 2019 | 158 | 0.040 |
Why?
|
| Thyroid Function Tests | 1 | 2018 | 40 | 0.040 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2021 | 562 | 0.040 |
Why?
|
| Random Allocation | 1 | 2020 | 747 | 0.040 |
Why?
|
| Anorexia | 1 | 2019 | 148 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2004 | 1666 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2021 | 326 | 0.040 |
Why?
|
| Homeostasis | 1 | 2003 | 960 | 0.040 |
Why?
|
| Clone Cells | 1 | 2019 | 592 | 0.040 |
Why?
|
| Forecasting | 1 | 2021 | 707 | 0.040 |
Why?
|
| Exosomes | 1 | 2021 | 252 | 0.040 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 3 | 2003 | 76 | 0.040 |
Why?
|
| Paraffin Embedding | 1 | 2018 | 226 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2021 | 641 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2002 | 879 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2019 | 7294 | 0.030 |
Why?
|
| Receptors, Interleukin-7 | 1 | 2016 | 49 | 0.030 |
Why?
|
| Genotype | 1 | 2024 | 4109 | 0.030 |
Why?
|
| ROC Curve | 1 | 2020 | 1221 | 0.030 |
Why?
|
| Dasatinib | 1 | 2020 | 881 | 0.030 |
Why?
|
| California | 1 | 2016 | 211 | 0.030 |
Why?
|
| Inflammation | 3 | 2014 | 2527 | 0.030 |
Why?
|
| Comprehension | 1 | 2016 | 104 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2004 | 852 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 1323 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2002 | 1135 | 0.030 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 14 | 2 | 2005 | 5 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2016 | 2465 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2018 | 580 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 3542 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2017 | 759 | 0.030 |
Why?
|
| Neutropenia | 1 | 2019 | 1001 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2011 | 4840 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2018 | 791 | 0.030 |
Why?
|
| Lymphocytes | 2 | 2014 | 1269 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2017 | 1153 | 0.030 |
Why?
|
| Newcastle disease virus | 1 | 2014 | 7 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 1745 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2019 | 1132 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 2368 | 0.030 |
Why?
|
| Mice, Knockout | 4 | 2005 | 5837 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 872 | 0.030 |
Why?
|
| Anemia | 1 | 2019 | 730 | 0.030 |
Why?
|
| Biopsy | 1 | 2021 | 3545 | 0.030 |
Why?
|
| Survival | 1 | 2013 | 184 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2013 | 182 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2024 | 4327 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 1467 | 0.030 |
Why?
|
| Indoles | 1 | 2018 | 1035 | 0.030 |
Why?
|
| Piperidines | 1 | 2018 | 1089 | 0.030 |
Why?
|
| Castration | 1 | 2012 | 128 | 0.030 |
Why?
|
| Interferon Type I | 1 | 2014 | 283 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2018 | 1124 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2016 | 662 | 0.030 |
Why?
|
| Oncolytic Viruses | 1 | 2014 | 165 | 0.030 |
Why?
|
| Spleen | 2 | 2005 | 736 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2020 | 13352 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 5042 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 7813 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 1985 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2020 | 6248 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 2 | 2002 | 228 | 0.020 |
Why?
|
| Antibodies | 1 | 2013 | 835 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2004 | 5494 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2013 | 1719 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2005 | 1617 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2021 | 10250 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2019 | 6027 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 9043 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 958 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2024 | 9078 | 0.020 |
Why?
|
| Genomics | 1 | 2017 | 2817 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 3245 | 0.020 |
Why?
|
| Lymphotoxin beta Receptor | 1 | 2005 | 4 | 0.020 |
Why?
|
| Hepatomegaly | 1 | 2005 | 72 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2005 | 6 | 0.020 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2005 | 173 | 0.020 |
Why?
|
| Concanavalin A | 1 | 2005 | 70 | 0.020 |
Why?
|
| Ethylnitrosourea | 1 | 2004 | 20 | 0.020 |
Why?
|
| Transcriptome | 1 | 2013 | 1934 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2004 | 126 | 0.010 |
Why?
|
| B7-2 Antigen | 1 | 2003 | 53 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 2004 | 222 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2017 | 5188 | 0.010 |
Why?
|
| DNA Methylation | 1 | 2013 | 2736 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2005 | 350 | 0.010 |
Why?
|
| Mice, Inbred MRL lpr | 1 | 2002 | 26 | 0.010 |
Why?
|
| Ligands | 1 | 2005 | 1061 | 0.010 |
Why?
|
| Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2002 | 8 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 4182 | 0.010 |
Why?
|
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2002 | 37 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fyn | 1 | 2002 | 34 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2002 | 41 | 0.010 |
Why?
|
| Myelin-Associated Glycoprotein | 1 | 2002 | 18 | 0.010 |
Why?
|
| Models, Immunological | 1 | 2002 | 80 | 0.010 |
Why?
|
| Thymus Gland | 1 | 2003 | 310 | 0.010 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2002 | 42 | 0.010 |
Why?
|
| Disease Progression | 1 | 2013 | 6893 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2002 | 209 | 0.010 |
Why?
|
| Membrane Microdomains | 1 | 2002 | 83 | 0.010 |
Why?
|
| Inducible T-Cell Co-Stimulator Ligand | 1 | 2001 | 22 | 0.010 |
Why?
|
| Schistosoma mansoni | 1 | 2001 | 35 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 2002 | 115 | 0.010 |
Why?
|
| Myelin Proteins | 1 | 2002 | 93 | 0.010 |
Why?
|
| fas Receptor | 1 | 2002 | 200 | 0.010 |
Why?
|
| Cell Differentiation | 2 | 2003 | 4191 | 0.010 |
Why?
|
| Inducible T-Cell Co-Stimulator Protein | 1 | 2001 | 77 | 0.010 |
Why?
|
| DNA Replication | 1 | 2005 | 772 | 0.010 |
Why?
|
| Mice, Inbred NOD | 1 | 2003 | 911 | 0.010 |
Why?
|
| Oncogenes | 1 | 2004 | 700 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2002 | 496 | 0.010 |
Why?
|
| Immunoglobulin E | 1 | 2001 | 182 | 0.010 |
Why?
|
| Antigens, Helminth | 1 | 2001 | 188 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2002 | 635 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2004 | 1397 | 0.010 |
Why?
|
| Secondary Prevention | 1 | 2002 | 322 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2003 | 891 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 22059 | 0.010 |
Why?
|
| Hepatectomy | 1 | 2005 | 1012 | 0.010 |
Why?
|
| Cell Survival | 1 | 2003 | 3081 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 2002 | 1424 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2001 | 1884 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2002 | 4644 | 0.010 |
Why?
|
| Risk Factors | 1 | 2012 | 17824 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 3126 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2004 | 6483 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 6789 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2002 | 4985 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2003 | 3067 | 0.010 |
Why?
|